ATE297735T1 - Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff - Google Patents
Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoffInfo
- Publication number
- ATE297735T1 ATE297735T1 AT01910421T AT01910421T ATE297735T1 AT E297735 T1 ATE297735 T1 AT E297735T1 AT 01910421 T AT01910421 T AT 01910421T AT 01910421 T AT01910421 T AT 01910421T AT E297735 T1 ATE297735 T1 AT E297735T1
- Authority
- AT
- Austria
- Prior art keywords
- antimuscarine
- inhibitor
- act
- new active
- active combination
- Prior art date
Links
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 title 1
- 229930182837 (R)-adrenaline Natural products 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 229960005139 epinephrine Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18479000P | 2000-02-24 | 2000-02-24 | |
| PCT/US2001/003698 WO2001062236A2 (en) | 2000-02-24 | 2001-01-23 | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE297735T1 true ATE297735T1 (de) | 2005-07-15 |
Family
ID=22678338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01910421T ATE297735T1 (de) | 2000-02-24 | 2001-02-23 | Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20020010216A1 (de) |
| EP (1) | EP1257277B1 (de) |
| JP (1) | JP2003523382A (de) |
| CN (2) | CN1660435A (de) |
| AR (1) | AR027956A1 (de) |
| AT (1) | ATE297735T1 (de) |
| AU (1) | AU781254B2 (de) |
| CA (1) | CA2399442A1 (de) |
| DE (1) | DE60111500T2 (de) |
| DK (1) | DK1257277T3 (de) |
| ES (1) | ES2241802T3 (de) |
| MX (1) | MXPA02008183A (de) |
| NZ (1) | NZ520975A (de) |
| PE (1) | PE20011306A1 (de) |
| PT (1) | PT1257277E (de) |
| WO (1) | WO2001062236A2 (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1632235A3 (de) * | 1999-07-01 | 2006-06-14 | Pharmacia & Upjohn Company LLC | Verwendung von hochselektiven Norepinephrin-Aufnahme-Inhibitoren zur Behandlung von mentalen Erkrankungen |
| DE60022692T2 (de) | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen |
| BR0211522A (pt) * | 2001-07-31 | 2004-09-14 | Upjohn Co | Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| DE10146275A1 (de) | 2001-09-18 | 2003-04-24 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| CA2466649A1 (en) * | 2001-11-30 | 2003-06-12 | Eli Lilly & Company | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders |
| CA2475763A1 (en) * | 2002-02-12 | 2003-08-21 | Cypress Bioscience, Inc. | Methods of treating attention deficit/hyperactivity disorder (adhd) |
| CA2479350A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| US7754242B2 (en) * | 2002-03-20 | 2010-07-13 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
| AR039164A1 (es) * | 2002-03-28 | 2005-02-09 | Synthon Bv | Sales de venlafaxina de baja solubilidad en agua |
| WO2003082804A1 (en) * | 2002-03-28 | 2003-10-09 | Synthon B.V. | Venlafaxine besylate |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| US20070196481A1 (en) * | 2002-07-25 | 2007-08-23 | Amidon Gregory E | Sustained-release tablet composition |
| US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
| PA8578501A1 (es) * | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| AU2003268361A1 (en) * | 2002-08-30 | 2004-03-19 | Watson Pharmaceuticals, Inc. | Drug delivery system for treating urinary incontinence |
| EP1558231A4 (de) * | 2002-10-03 | 2010-09-08 | Cypress Bioscience Inc | Dosiseskalation und geteilte tagesdosis von antidepressiva zurbehandlung von neurologischen erkrankungen |
| US6974820B2 (en) * | 2002-11-06 | 2005-12-13 | Bridge Pharma, Inc. | Methods for treating urinary incontinence and other disorders using trospium |
| EP1424079A1 (de) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| WO2004058353A2 (en) * | 2002-12-24 | 2004-07-15 | Paradigm Therapeutics Ltd. | Therapeutic use of selective noradrenaline reuptake inhibitors |
| US6943193B1 (en) * | 2003-01-21 | 2005-09-13 | Jordan A. Altabet | Method for treating sexual dysfunction |
| PT1601349E (pt) | 2003-02-14 | 2008-10-27 | Pf Medicament | Utilização do enantiómero (1s, 2r) do milnaciprano para a preparação de um medicamento |
| FR2851163B1 (fr) | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| JP2006522144A (ja) * | 2003-04-04 | 2006-09-28 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 下部尿路障害の治療方法 |
| JP2006524708A (ja) * | 2003-04-25 | 2006-11-02 | インディヴァス ファーマシューティカルズ，インコーポレーテッド | 塩化トロスピウムの投与により連続睡眠を促進するための方法 |
| CA2536161A1 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| DE602004030931D1 (de) | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| UA93608C2 (ru) * | 2004-08-13 | 2011-02-25 | Берингер Ингельхайм Интернациональ Гмбх | композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ |
| CN101022788B (zh) * | 2004-08-13 | 2010-11-10 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途 |
| WO2006096434A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US20060287347A1 (en) * | 2005-06-21 | 2006-12-21 | Aberg A K G | Methods for treating smooth muscle disorders using trospium |
| US7390816B2 (en) * | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| US20070004766A1 (en) * | 2005-07-01 | 2007-01-04 | Aberg A K G | Methods for relaxation of smooth muscle contractions using Trospium |
| JP2009503020A (ja) * | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
| EP1988875A2 (de) * | 2006-02-10 | 2008-11-12 | Boehringer Ingelheim International GmbH | Modifizierte freisetzungsformulierung |
| MX2008013827A (es) * | 2006-05-09 | 2008-11-10 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual. |
| EP2037927B1 (de) * | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
| WO2008006838A1 (en) * | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Use of flibanserin for the treatment of sexual disorders in females |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| JP5793828B2 (ja) | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
| KR20090045945A (ko) * | 2006-08-25 | 2009-05-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 제어 방출 시스템 및 이의 제조방법 |
| US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
| WO2008090742A1 (ja) * | 2007-01-23 | 2008-07-31 | National University Corporation Hokkaido University | 眼疾患モデル用非ヒト動物 |
| EP2175843B1 (de) | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Tolterodinhaltige zusammensetzungen mit verzögerter freisetzung |
| CL2008002693A1 (es) * | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| IT1392333B1 (it) * | 2008-12-16 | 2012-02-28 | Giofarma S R L | Preparazione farmaceutica per il trattamento di patologie depressive, contenente una proteina con elevato rapporto triptofano/lnaa |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| PT3061821T (pt) | 2009-07-22 | 2019-09-05 | PureTech Health LLC | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
| WO2011057176A1 (en) | 2009-11-06 | 2011-05-12 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
| EP2558437B1 (de) * | 2010-04-12 | 2015-08-05 | Supernus Pharmaceuticals, Inc. | Verfahren zur herstellung von viloxazinsalzen und neue polymorphe daraus |
| US20120289744A1 (en) | 2010-11-03 | 2012-11-15 | Arch Pharmalabs Limited | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts |
| GEAP202416602A (en) * | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| KR102874891B1 (ko) * | 2018-01-30 | 2025-10-21 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 방법 및 조성물 |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| KR102408292B1 (ko) | 2018-09-28 | 2022-06-10 | 카루나 세러퓨틱스 인코포레이티드 | 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법 |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| MX2021004883A (es) * | 2018-10-31 | 2021-08-05 | Apnimed Inc Delaware | Metodos y composiciones para tratar apnea del sue?o. |
| CN118557736A (zh) | 2019-02-08 | 2024-08-30 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| JP7776442B2 (ja) | 2020-05-05 | 2025-11-26 | アプニメッド，インコーポレイテッド（デラウェア） | （ｒ）－オキシブチニン塩酸塩の多形形態 |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2002492A1 (en) * | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
| GB9517883D0 (en) * | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
-
2001
- 2001-01-23 PT PT01910421T patent/PT1257277E/pt unknown
- 2001-01-23 WO PCT/US2001/003698 patent/WO2001062236A2/en not_active Ceased
- 2001-01-23 NZ NZ520975A patent/NZ520975A/en unknown
- 2001-01-23 CN CN2005100039430A patent/CN1660435A/zh active Pending
- 2001-01-23 MX MXPA02008183A patent/MXPA02008183A/es active IP Right Grant
- 2001-01-23 JP JP2001561303A patent/JP2003523382A/ja active Pending
- 2001-01-23 CN CN01804031A patent/CN1396829A/zh active Pending
- 2001-02-16 PE PE2001000175A patent/PE20011306A1/es not_active Application Discontinuation
- 2001-02-23 EP EP01910421A patent/EP1257277B1/de not_active Expired - Lifetime
- 2001-02-23 US US09/792,718 patent/US20020010216A1/en not_active Abandoned
- 2001-02-23 AT AT01910421T patent/ATE297735T1/de not_active IP Right Cessation
- 2001-02-23 AU AU38028/01A patent/AU781254B2/en not_active Ceased
- 2001-02-23 DK DK01910421T patent/DK1257277T3/da active
- 2001-02-23 CA CA002399442A patent/CA2399442A1/en not_active Abandoned
- 2001-02-23 AR ARP010100838A patent/AR027956A1/es unknown
- 2001-02-23 DE DE60111500T patent/DE60111500T2/de not_active Expired - Fee Related
- 2001-02-23 ES ES01910421T patent/ES2241802T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AR027956A1 (es) | 2003-04-16 |
| US20020010216A1 (en) | 2002-01-24 |
| CN1396829A (zh) | 2003-02-12 |
| NZ520975A (en) | 2004-03-26 |
| CA2399442A1 (en) | 2001-08-30 |
| WO2001062236A2 (en) | 2001-08-30 |
| DE60111500T2 (de) | 2006-05-18 |
| PE20011306A1 (es) | 2001-12-29 |
| EP1257277B1 (de) | 2005-06-15 |
| CN1660435A (zh) | 2005-08-31 |
| PT1257277E (pt) | 2005-09-30 |
| AU3802801A (en) | 2001-09-03 |
| EP1257277A2 (de) | 2002-11-20 |
| DE60111500D1 (de) | 2005-07-21 |
| ES2241802T3 (es) | 2005-11-01 |
| MXPA02008183A (es) | 2002-11-29 |
| JP2003523382A (ja) | 2003-08-05 |
| DK1257277T3 (da) | 2005-09-12 |
| WO2001062236A3 (en) | 2002-03-07 |
| AU781254B2 (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE297735T1 (de) | Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff | |
| NO20024528L (no) | Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen | |
| ID30590A (id) | Celana sekali pakai jenis-celana pendek | |
| AR027993A1 (es) | Inhibidores de carbonato de caspasa y usos del mismo | |
| DK1282611T3 (da) | Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer | |
| PT1326853E (pt) | Novos tiadiazoles e oxadiazoles e sua utilizacao como inibidores da fosfodiesterase-7 | |
| DK1305301T3 (da) | Alpha-acyl- og alpha-heteroatomsubstituerede benzenacetamidglucokinase-aktivatorer | |
| ATE298337T1 (de) | Neue verwendung sowie neue n-azabicycloamid- verbindungen | |
| DE60003148D1 (de) | Bestimmung der Cachezeit | |
| PT1296564E (pt) | Concentrado liquido para granizado e metodo para o fabrico do mesmo | |
| NO992492D0 (no) | Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer | |
| EP1248642A4 (de) | Peptidomimetischer inhibitor von vegf sowie vegf-c und -d | |
| NO20005265D0 (no) | Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser | |
| PL370766A1 (en) | Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors | |
| DE60106968D1 (de) | Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren | |
| DE60143864D1 (de) | Positive chemisch verstärkte Resistzusammensetzung | |
| FI20001715L (fi) | Rankoihin liittyvõt jõrjestelyt ja menetelmõt | |
| DE60109179D1 (de) | Quantenkaskadierter laser | |
| MXPA03003796A (es) | Procedimiento y dispositivos de aplicacion por vertido. | |
| AR028068A1 (es) | Nuevos derivados de 1,1-dioxotiocromano y su uso como inhibidores de trombina | |
| FI20040531A7 (fi) | Insuliiniresistenttien tilojen hoitaminen ja diagnosointi | |
| DE50203882D1 (de) | Mittel, die die apoptose bei an der wundheilung beteiligten zellen inhibieren | |
| AR028122A1 (es) | Nuevos compuestos aminotiolésteres, composiciones farmacéuticas y cosméticas que los contienen y utilizaciones | |
| EE200300507A (et) | HIV proteaasi inhibiitorite kasutamine rakkude migratsiooni ja/või invasiooni, koe infiltratsiooni ja turse tekkimise blokeerimiseks | |
| ATA10362000A (de) | Umhüllung von vorspannelementen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1257277 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |